Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts - PubMed (original) (raw)
. 1995 May 1;85(9):2607-18.
Affiliations
- PMID: 7537122
Free article
Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts
B R Blazar et al. Blood. 1995.
Free article
Abstract
We have developed an in vitro system in which C57BL/6 donor splenocytes are exposed to B10.BR host alloantigens in the context of deficient CD28:B7 signaling as a means of preventing graft-versus-host disease (GVHD). Although 54% to 82% of MLR alloresponse was inhibited by cytotoxic T-lymphocyte antigen 4 (CTLA4)-Ig treatment of host stimulator cells, treated splenocytes were still capable of causing GVHD when infused in vivo. By adding anti-leukocyte function antigen 1 (anti-LFA1) antibody to hCTLA4-Ig in vitro to coblock the LFA1:intercellular adhesion molecule (ICAM) signaling, splenic alloresponse was inhibited by > or = 89%, yet GVHD induction capabilities were retained. Because antigen-primed cells might be more susceptible to CD28:B7 blockade, we investigated whether hCTLA4-Ig alone, anti-LFA1 antibody alone, or the combination of both added to donor-antihost in vitro primed cells could reduce GVHD. To facilitate hyporesponsiveness induction and to block B7 and ICAM ligands that are upregulated during GVHD, these reagents were also administered to recipients post-BMT. We have shown that hCTLA4-Ig plus anti-LFA1 antibody is highly effective in preventing GVHD-induced lethality (88% to 100% of treated mice surviving versus 0% to 28% of controls surviving). For optimal prevention, both hCTLA4-Ig and anti-LFA1 must be used in vitro in the context of donor-antihost primed splenocytes and continued in vivo. This in vitro-in vivo combined approach was associated with donor engraftment, and recipients were not globally immunosuppressed. We conclude that blocking both the CD28/B7 and the LFA1:ICAM pathways are critical to effective GVHD prevention and may offer advantages to in vitro donor T-cell removal.
Similar articles
- Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Blazar BR, et al. J Immunol. 1999 Jun 1;162(11):6368-77. J Immunol. 1999. PMID: 10352249 - CD28/B7 costimulation: a review.
Greenfield EA, Nguyen KA, Kuchroo VK. Greenfield EA, et al. Crit Rev Immunol. 1998;18(5):389-418. doi: 10.1615/critrevimmunol.v18.i5.10. Crit Rev Immunol. 1998. PMID: 9784967 Review. - CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW, Barcy S, Devos S, Vandenberghe P, Ceuppens JL, Thielemans K, de Boer M. van Gool SW, et al. Res Immunol. 1995 Mar-Apr;146(3):183-96. doi: 10.1016/0923-2494(96)80256-2. Res Immunol. 1995. PMID: 8525052 Review. No abstract available.
Cited by
- The effect of ADAMTS13 on graft-versus-host disease.
Li D, Cho MS, Gonzalez-Delgado R, Liang X, Dong JF, Cruz MA, Ma Q, Afshar-Kharghan V. Li D, et al. J Cell Mol Med. 2024 Jul;28(13):e18457. doi: 10.1111/jcmm.18457. J Cell Mol Med. 2024. PMID: 38963011 Free PMC article. - Human Wnt/β-Catenin Regulates Alloimmune Signaling during Allogeneic Transplantation.
Mammadli M, Harris R, Mahmudlu S, Verma A, May A, Dhawan R, Waickman AT, Sen JM, August A, Karimi M. Mammadli M, et al. Cancers (Basel). 2021 Jul 28;13(15):3798. doi: 10.3390/cancers13153798. Cancers (Basel). 2021. PMID: 34359702 Free PMC article. - Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice.
Yue X, Petersen F, Shu Y, Kasper B, Magatsin JDT, Ahmadi M, Yin J, Wax J, Wang X, Heidecke H, Lamprecht P, Müller A, Yu X, Riemekasten G. Yue X, et al. Front Immunol. 2021 Jun 23;12:677970. doi: 10.3389/fimmu.2021.677970. eCollection 2021. Front Immunol. 2021. PMID: 34248959 Free PMC article. - The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S, Leigh ND, Cao X. Kumar S, et al. Front Immunol. 2018 Dec 21;9:3003. doi: 10.3389/fimmu.2018.03003. eCollection 2018. Front Immunol. 2018. PMID: 30627129 Free PMC article. Review. - Anti-LFA-1 induces CD8 T-cell dependent allograft tolerance and augments suppressor phenotype CD8 cells.
Plenter RJ, Grazia TJ, Coulombe MG, Nelsen MK, Lin CM, Scott Beard K, Kupfer TM, Zamora MR, Gill RG, Pietra BA. Plenter RJ, et al. Cell Immunol. 2018 Oct;332:101-110. doi: 10.1016/j.cellimm.2018.08.003. Epub 2018 Aug 7. Cell Immunol. 2018. PMID: 30103941 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical